近日该股表现 | 日期 | 当日涨跌幅（%） | 换手率（%） | 主力资金净流入（万元） | | --- | --- | --- | --- | | 2025.07.29 | 10.02 | 25.98 | -4328.97 | | 2025.07.28 | 9.95 | 25.53 | 16400.16 | | 2025.07.25 | 6.63 | 36.81 | 29390.09 | | 2025.07.24 | -2.58 | 24.30 | -6992.00 | | 2025.07.23 | 4.23 | 27.95 | 4495.73 | | 2025.07.22 | -4.24 | 37.02 | -6932.73 | | 2025.07.21 | 9.92 | 27.18 | 18102.33 | | 2025.07.18 | 1.86 | 39.19 | -14546.71 | | 2025.07.17 | 9.98 | 22.88 | -2444.23 | | 2025.07.16 | 9.98 | 20.61 | 5770.24 | （文章来源：证券时报网） 证券时报·数据宝统计，两融 ...

Market Overview - A-shares have seen a significant increase in activity, with the Shanghai Composite Index surpassing 3600 points and reaching a new high, while the ChiNext Index broke through 2400 points, entering a technical bull market [1] Hot Stocks - The top ten hot stocks in A-shares include Xizang Tianlu, Shanhe Intelligent, Hengsheng Electronics, WuXi AppTec, Baogang Co., Asia-Pacific Pharmaceutical, China Power Construction, Xining Special Steel, Zhongyin Securities, and Northern Rare Earth [2] Industry Trends - The Yarlung Tsangpo River downstream hydropower project concept has resurfaced, with Xizang Tianlu, Shanhe Intelligent, and China Power Construction being the leading stocks. Xizang Tianlu holds over 60% market share in the cement sector, benefiting from geographical advantages [3] - The national-level strategic project, with a total investment of 1.2 trillion yuan, is expected to require over 40 million tons of cement and an annual infrastructure investment of 80 billion yuan, stimulating demand across the construction materials, engineering machinery, and hydropower sectors [3] Company Performance - Northern Rare Earth and Baogang Co. confirmed their successful bids for the Yarlung Tsangpo hydropower project's rare earth alloy steel project, with Northern Rare Earth's net profit surging 18 to 20 times year-on-year, driven by rising prices and volumes of rare earth products [3] - Baogang Co. raised its third-quarter rare earth concentrate transaction prices by 14.14%, enhancing performance growth expectations [3] - Hengsheng Electronics saw a surge in interest following Hong Kong's implementation of a regulatory framework for stablecoin issuers, alongside news of Ant Group applying for a stablecoin license, leading to strong market expectations for potential collaboration [3] Financial Results - WuXi AppTec reported a record high revenue of 20.8 billion yuan and a net profit of 8.56 billion yuan for the first half of the year. The easing of geopolitical risks and supportive policies for innovative drugs have contributed to this performance [4] - Asia-Pacific Pharmaceutical's mid-year performance is expected to increase over 17 times, primarily due to non-recurring income from the sale of a subsidiary, along with advantages from its product line [4] - WuXi AppTec plans to raise its share repurchase price limit from 90.72 yuan to 114.15 yuan, which has positively impacted market sentiment [4]

证券日报网讯 7月29日晚间，亚太药业发布公告称，公司股票于2025年7月25日、2025年7月28日、2025 年7月29日连续三个交易日收盘价格涨幅偏离值累计超过20%，属于股票交易异常波动。经核实，公司 前期披露的信息不存在需要更正、补充之处。公司未发现近期公共传媒报道了可能或已经对公司股票交 易价格产生较大影响的未公开重大信息。 （编辑 姚尧） ...

亚太药业7月29日交易公开信息 | 买/ | 会员营业部名称 | 买入金额（万 | 卖出金额（万 | | --- | --- | --- | --- | | 卖 | | 元） | 元） | | 买一 | 机构专用 | 4412.41 | 1512.52 | | 买二 | 国泰海通证券股份有限公司深圳福田中心区华融大厦证券营 业部 | 2255.04 | 535.26 | | 买三 | 国新证券股份有限公司长沙韶山路证券营业部 | 1506.40 | 1584.87 | | 买四 | 机构专用 | 1490.67 | 4944.59 | | 买五 | 海通证券股份有限公司北京中关村南大街证券营业部 | 1358.55 | 9.37 | | 卖一 | 机构专用 | 1490.67 | 4944.59 | | 卖二 | 机构专用 | 1267.83 | 2152.13 | | 卖三 | 国金证券股份有限公司深圳分公司 | 872.39 | 1871.74 | | 卖四 | 华泰证券股份有限公司深圳前海证券营业部 | 2.51 | 1675.77 | | 卖五 | 国新证券股份有限公司长沙韶山路证券营业部 | 150 ...

证券代码：002370 证券简称：亚太药业 公告编号：2025-064 浙江亚太药业股份有限公司 关于股票交易异常波动公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 一、股票交易异常波动的情况 浙江亚太药业股份有限公司（以下简称"亚太药业"或"公司"） 股票（证券简称：亚太药业，证券代码：002370）于 2025 年 7 月 25 日、2025 年 7 月 28 日、2025 年 7 月 29 日连续三个交易日收盘价格 涨幅偏离值累计超过 20％，根据深圳证券交易所的有关规定，属于股 票交易异常波动的情况。 二、公司关注并核实情况说明 针对公司股票异常波动，公司就有关事项进行了核实，现将有关 情况说明如下： 三、不存在应披露而未披露信息的说明 本公司董事会确认，本公司目前没有任何根据《深圳证券交易所 股票上市规则》等有关规定应予以披露而未披露的事项；董事会也未 获悉公司有根据《深圳证券交易所股票上市规则》等有关规定应予以 披露而未披露的、对公司股票及其衍生品种交易价格产生较大影响的 信息；公司前期披露的信息不存在需要更正、补充之处。 1、公司前期披露的 ...

浙江亚太药业股份有限公司（证券代码：002370）公告称，公司股票于2025年7月25日、28日、29日连 续三个交易日收盘价格涨幅偏离值累计超过20%，触及深圳证券交易所股票交易异常波动标准。公司核 实确认，前期披露信息无需更正或补充，近期未出现可能影响股价的未公开重大信息，经营情况及内外 部环境未发生重大变化；公司、控股股东及实控人不存在应披露未披露重大事项，且异常波动期间控股 股东及实控人未买卖公司股票。 ...

今日涨跌幅居前的概念板块 | 概念 | 今日涨跌幅（%） | 概念 | 今日涨跌幅（%） | | --- | --- | --- | --- | | CRO概念 | 4.00 | 猪肉 | -1.35 | | 重组蛋白 | 2.90 | 养鸡 | -1.12 | | 创新药 | 2.79 | 草甘膦 | -1.10 | | 减肥药 | 2.76 | 粮食概念 | -1.00 | | F5G概念 | 2.43 | 芬太尼 | -0.88 | | 细胞免疫治疗 | 2.42 | PEEK材料 | -0.85 | | 仿制药一致性评价 | 2.30 | 预制菜 | -0.85 | | 共封装光学(CPO) | 2.23 | 生态农业 | -0.78 | | 特钢概念 | 2.08 | C2M概念 | -0.78 | | 先进封装 | 1.91 | 人造肉 | -0.76 | 截至7月29日收盘，仿制药一致性评价概念上涨2.30%，位居概念板块涨幅第7，板块内，104股上涨， 亚太药业、九洲药业、辰欣药业等涨停，南新制药、苑东生物、海特生物等涨幅居前，分别上涨 17.01%、15.45%、15.28%。跌幅居前的有昂 ...

Core Viewpoint - The chemical pharmaceutical sector experienced a significant increase of 2.47% on July 29, with Nanjing Pharmaceutical leading the gains [1] Group 1: Market Performance - The Shanghai Composite Index closed at 3609.71, up 0.33% [1] - The Shenzhen Component Index closed at 11289.41, up 0.64% [1] Group 2: Individual Stock Performance - Nanjing Pharmaceutical (681899) closed at 11.90, with a rise of 17.01% and a trading volume of 388,700 shares, totaling a transaction value of 417 million yuan [1] - Yuandong Biological (688513) closed at 65.92, up 15.45%, with a trading volume of 74,200 shares and a transaction value of 466 million yuan [1] - Microchip Biotech (688321) closed at 38.37, increasing by 12.85%, with a trading volume of 401,800 shares and a transaction value of 1.49 billion yuan [1] - Aoxiang Pharmaceutical (603229) closed at 10.54, up 10.02%, with a trading volume of 480,600 shares and a transaction value of 493 million yuan [1] - Asia-Pacific Pharmaceutical (002370) closed at 6.81, also up 10.02%, with a trading volume of 1,937,200 shares and a transaction value of 1.285 billion yuan [1] - Chenxin Pharmaceutical (603367) closed at 25.93, up 10.01%, with a trading volume of 160,000 shares and a transaction value of 413 million yuan [1] - Fuyuan Pharmaceutical (6801089) closed at 22.90, increasing by 9.99%, with a trading volume of 176,900 shares and a transaction value of 389 million yuan [1] - Nikan Pharmaceutical (688658) closed at 33.02, up 9.96%, with a trading volume of 118,700 shares and a transaction value of 376 million yuan [1] - Luoxin Pharmaceutical (002793) closed at 5.97, increasing by 9.94%, with a trading volume of 421,300 shares and a transaction value of 240 million yuan [1] - Frontier Biotech (688221) closed at 22.42, up 9.74%, with a trading volume of 471,400 shares and a transaction value of 1.023 billion yuan [1] Group 3: Capital Flow - The chemical pharmaceutical sector saw a net inflow of 1.295 billion yuan from main funds, while retail funds experienced a net outflow of 1.198 billion yuan [1] - Speculative funds recorded a net outflow of 97.108 million yuan [1]

Group 1 - The market saw a total of 31 stocks hitting the daily limit up, with a success rate of 63% for limit up attempts [1] - Xizang Tourism became a market focus, achieving a consecutive limit up for 7 trading days, making it a representative high-limit stock [1] - Innovative drug concept stocks showed strong performance, with Apac Pharmaceutical achieving 5 limit ups in 10 trading days due to improved earnings expectations from a subsidiary sale [1] Group 2 - The overall market performance indicated a slight decline in the Shanghai Composite Index by 0.08% and Shenzhen Component Index by 0.04%, while the ChiNext Index rose by 0.92% [1] - The total trading volume in the three major markets reached 11,460.26 billion yuan, with 3,901 stocks declining and 1,468 stocks rising [1] - The chemical pharmaceutical sector attracted the highest net inflow of funds at 1.568 billion yuan, followed by the biopharmaceutical sector with 1.245 billion yuan [1] Group 3 - Other stocks that hit the limit up included Xingfu Blue Ocean, Kejingyuan, and Haichang New Materials, with some ChiNext stocks achieving a 20% limit up, indicating strong market enthusiasm for related concepts [2] - Medical research outsourcing institutions (CRO) and contract development manufacturing organizations (CDMO) were among the top-performing sectors, along with FPGA chips and CXO medical outsourcing [2]

Core Viewpoint - The increasing number of individuals banned from the securities market in China reflects a tightening regulatory environment, with a notable rise in enforcement actions against market manipulation and financial fraud [1][7]. Group 1: Market Bans and Statistics - As of May 30, 2021, a total of 24 individuals have been banned from the securities market in China this year, a significant increase of over 40% compared to 17 individuals banned during the same period last year [2][7]. - Notable cases include Chen Jianming, the actual controller of ST Zhongchang, who was banned for manipulating the company's stock through 101 accounts, resulting in illegal profits of 11.47 million yuan [2][5]. Group 2: Types of Violations - The violations leading to market bans primarily fall into three categories: failure to disclose significant company matters, false or misleading information disclosures, and market manipulation [4][5]. - Specific cases include *ST Jinzheng and other companies where executives were banned for failing to disclose major issues and engaging in fraudulent activities [3][4]. Group 3: Regulatory Environment - The China Securities Regulatory Commission (CSRC) has emphasized a stricter approach to combating fraudulent activities, including financial fraud and market manipulation, with plans to enhance regulatory measures [6][7]. - The CSRC is also in the process of revising the Securities Market Ban Regulations to include new categories of bans and expand the scope of individuals subject to these bans [7][8].